The China Leukemia Therapeutics Market size stood at USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
The Chinese market for leukemia therapeutics is anticipated to experience a strong growth throughout the forecast period. The increasing number of cases of leukemia and the development of the healthcare infrastructure are predicted to accelerate the growth of the overall market throughout the forecast period. Increasing geriatric population is fueling the growth of this therapeutics market in china.
Increased prevalence of cancer especially blood cancer leads to rising demand for effective treatments. Rise in expenditure on development of novel treatment and developing health infrastructure is further fueling the market growth. Additionally, the rise in survival rate and minimum side effects of novel treatment such as stem cell therapy, bone marrow transplant has open new avenues for the market growth. Furthermore, increasingly exposed to chemical mutation, changing dietary habits, and living style of the population is further pushing the market growth.
The favourable government initiatives and the emergence of innovative therapeutics are predicted to generate promising growth opportunities for the leading players operating in the leukemia therapeutics market across the country. The rising investments for research & development activities and the increasing disposable income of consumers along with the rising prevalence of leukemia are anticipated to fuel the market’s growth in the forecast period.
Additionally, patients with blood cancer are 57% more likely to experience severe symptoms of COVID-19 than patients with other types of cancers. Given these and other similar findings, the demand for leukemia therapeutics has been soaring during the COVID-19 pandemic, with market players reporting increased sales.